참고문헌 (29)

1. Asan Medical Center. Disease information - osteoporosis. Available from http://www.amc.seoul.kr/asan/healthinfo/disease/diseaseDetail.do?contentId31611. Accessed January 20, 2021. 

2. Lee JS, Jang SO. A study on reference values and prevalence of osteoporosis in Korea: the Korea national health and nutrition examination survey 2008-2011. J Korean Off Stat 2013;18(2):42-65. 

3. Healthcare Bigdata Hub. Statistics of national disease - osteoporosis. Available from http://opendata.hira.or.kr/op/opc/olapMfrnIntrsIlnsInfo.do. Accessed January 20, 2021. 

4. Chun SW. Pharmacological treatment of osteoporosis. J Korean Med Assoc 2019;62(10):542-50. 

   상세보기

5. Ganesan K, Bansal P, Goyal A, Roane D. Bisphosphonate. Available from https://www.ncbi.nlm.nih.gov/books/NBK470248/#article18343.s9. Accessed February 08, 2020. 

6. Choi HJ. Treatment for osteoporosis: focusing for bisphosphonate therapy. Korean J Fam Pract 2013;3(1):16-24. 

7. Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 2005;165(3):346-7. 

   상세보기

8. FDA alert. Severe musculoskeletal pain a risk with bisphosphonates. Available from https://www.healio.com/endocrinology/bone-mineralmetabolism/news/print/endocrine-today/%7Bfafc5981-b3e5-4307-9ad8-2a192a433bbd%7D/fda-alert-severe-musculoskeletal-pain-arisk-with-bisphosphonates. Accessed November 5, 2019. 

9. Thiebaud D, Sauty A, Burckhardt P, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 1997;61(1):386-92. 

   상세보기

10. Ugurlar M. Alendronate- and risedronate-induced acute polyarthritis. Osteoporos Int 2016;27(1):3383-5. 

    상세보기

11. Kang MK, Yoon NK. A study of adverse drug event reporting systems in Korea. Korean J Community Pharm. 2019;5(1):56-65. 

12. Patient Safety Drug Management Division, Korean Pharmaceutical Association. Regional drug safety center information. Available from https://www.safepharm.or.kr/sub_2_1.do. Accessed May 10, 2021. 

13. Korea Institute of Drug Safety and Risk Management. Regional drug safety center information and history. Available from https://www.drugsafe.or.kr/iwt/ds/ko/community/EgovCenterGuide.do Accessed January 20, 2021. 

14. Jin XM, Kim YJ, Yang BR, Choi NK, Park BJ. The role of consumers in the spontaneous adverse drug events reporting. J Pharmacoepidemiol Risk Manag 2010;3(3):101-12. 

15. Kang DY. The active pharmacovigilance system: a postscript of visiting the harvard pilgrim health care institute. J Pharmacoepidemiol Risk Manag 2017;9:45-7. 

16. Gordis L. Epidemiology, 5th Ed. Philadelphia: Elsevier, 2014: 198-199. 

17. Mor A, H.Pillinger M, L.Wortmann R, J.Mitnick H. Drug-induced arthritic and connective tissue disorders. Semin Arthritis Rheum 2008;38(3):249-64. 

    상세보기

18. Adwan MH. An update on drug-induced arthritis. Rheumatology International. 2016;36(1):1089-97. 

    상세보기

19. Bannwarth B. Drug-Induced Musculoskeletal Disorders. Drug Saf 2007;30(1):27-46. 

    상세보기

20. Lewiecki EM. Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis 2010;1(3):115-28. 

    상세보기

21. Lee J, Lee EH, Jung JW, Kang HR, Cho SH. Public awareness of adverse drug reactions and pharmacovigilance system in Korea. J Pharmacoepidemiol Risk Manag 2012;5(2):68-77. 

22. Korean Medical Library Engine. Alendronate. Available from http://www.kmle.co.kr. Accessed February 26, 2021. 

23. Ministry of Food and Drug Safety. Change order for drug permission (bisphosphonate). Available from https://nedrug.mfds.go.kr/bbs/58/2182/. Accessed February 08, 2021. 

24. Bock O, Boerst H, Thomasius FE, et al. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact 2007;7(2):144-8. 

25. Kim JA, Yoon S, Kim LY, Kim DS. Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data. J Korean Med Sci 2017;32(5):718-728. 

    상세보기

26. Kim SH, Kim H. Pictogram design for the assessment of pediatric pain. Journal of Integrated Design Research 2019;18(4):115-29. 

27. Hazell L, Shakir SAW. Under-reporting of adverse drug reactions. Drug Saf 2006;29(5):385-96. 

    상세보기

28. Rothman ML, Beltran P, Cappelleri JC, Lipscomb J, Teschendorf B. Patient-reported outcomes: conceptual issues. Value Health 2007;10(Suppl 2):S66-75. 

    상세보기

29. Schmier JK, Halpern MT. Patient recall and recall bias of health state and health status. Expert Rev Pharmacoecon Outcomes Res 2004;4(2):159-63. 

    상세보기

저자의 다른 논문 :

이모세 (5)